U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
LEQSELVI delivered statistically significant efficacy across two Phase 3 clinical trials. At baseline, the average patient had only 13% scalp…
